Results 281 to 290 of about 146,560 (338)

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

Imaging Mass Cytometry-Based Immune Profiling of Human Peyer's Patches in Patients with Crohn's Disease. [PDF]

Eur J Immunol
Huck A, Rodriguez-Sillke Y, Bojarski C, Kunkel D, Kühl AA, Lehmann M, Bischoff P, Steinhoff U, Siegmund B, Glauben R.   +9 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Correlation of Point-of-Care Intestinal Ultrasound With Endoscopic Disease Severity in Crohn's Disease. [PDF]

JGH Open
Nagarajan KV, Krishnamurthy AN, Yelsangikar A, Patil N, Agarwal R, Indi S, Bang A, Reddy S, Bhat V, Bhat N.   +9 more
europepmc   +1 more source

Sclerosing cholangitis: Liver transplantation [PDF]

, 1989
Marsh, JW, Starzl, TE
core  

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Detection of autoantibodies against exocrine pancreas by double immunodiffusion testing [PDF]

, 1990
Horbach, E., Kaiser, Doris, Otte, M., Rögener, W., Scriba, Peter Christian, Stöcker, W.   +5 more
core  

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Management and Treatment of Perianal Fistulizing Crohn's Disease. [PDF]

Clin Exp Gastroenterol
Lee JJ, Lightner AL.
europepmc   +1 more source

Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS‐Induced Colitis by Regulating AMPK Signalling

Cell Proliferation, EarlyView.
Luteolin alleviates DSS‐induced ulcerative colitis in mice by targeting the NLRP3 inflammasome, as it shows no effect in NLRP3‐/‐ mice. It inhibits NLRP3 activation and IL‐1β secretion in macrophages by reducing ROS, mtROS and calcium levels via AMPK binding and signalling. Metabolomic changes suggest lipid metabolism involvement. Luteolin represents a
Lianxiang Luo, Fangfang Huang, Guixuan Fang, Yiming Sun, Liyan Deng, Yinglin Liao, Xinming Chen, Zhuosi Chen, Xinxun Lin   +8 more
wiley   +1 more source